Jakub Svoboda, MD, On Improving CR Rates With Next-generation CAR T Therapies
The associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.
Sham Mailankody, MBBS, on Further Research With ALLO-715
The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.
David Sallman, MD, on Updates From the AMELI-01 Trial of UCART123v1.2 for AML
The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.
Gerhard Ehninger, MD, on Managing Toxicities With Switchable CARs in AML
The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.
Hemgenix “Transformative” for Patients With Hemophilia B
Steven Pipe, MD, CS Mott Children’s Hospital, discussed the latest follow-up data from the HOPE-B study of the approved therapy, Hemgenix.
Akshay Sharma, MBBS, on Investigating CRISPR/Cas9 Edited Cells for Sickle Cell Disease
The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed advantages of OTQ923 in treating SCD.
Armin Ghobadi, MD, on Assessing CAR-T Cell Combination Therapies
The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.
Advocating for Patients With Chronic Lymphocytic Leukemia
Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, Co-Founder, Executive Vice President, and Chief Medical Officer, CLL Society, discussed the role the society plays in the field.
Ivan Horak, MD, on Early Clinical Efficacy of Allogeneic CD30.CAR EBVST Cell Therapy in Lymphomas
The chief medical and scientific officer of Tessa Therapeutics discussed data from the BESTA and CHARIOT studies presented at ASH 2022.
Giedre Krenciute, PhD, on Revitalizing T-cells in CAR T-cell Therapy
The assistant member of the bone marrow transplantation and cellular therapy department at St. Jude Children’s Hospital discussed preclinical research presented at ASH 2022.
Rebecca Epperly, MD, on Emerging Clinical Research With Cell Therapy in Leukemia, Lymphoma
The clinician scientist at St. Jude Children’s Research Hospital discussed the session on cell therapies in acute leukemias and Hodgkin lymphoma she moderated at ASH 2022.
Paulina Velasquez, MD, on Finding New Targets for Cell Therapy
The assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.
Developing Nonviral Gene Therapy for Hemophilia A
Brent Warner, president, gene therapy, Poseida Therapeutics, discussed data on the preclinical P-FVIII-101 presented at ASH 2022.
Cilta-cel Garners More Positive Data in Early and Late Relapsed Multiple Myeloma Treatment
Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.
Jakub Svoboda, MD, on Promising Efficacy With huCART19-IL18 in NHL, CHL
The associate professor of medicine from University of Pennsylvania discussed updated data on huCART19-IL18 presented at the ASH 2022 meeting.
Swati Naik, MBBS, on Investigating CD123-CAR T Therapy for Relapsed AML
The assistant member at St. Jude Children’s Research Hospital discussed updated data from a phase 1 study being conducted at the hospital.
BCMA/CD19 CAR T Shows Efficacy in Newly Diagnosed Multiple Myeloma
Updated data were presented at the ASH 2022 annual meeting.
Real-World Axi-Cel Data Show QOL Improvements in LBCL
The first year after treatment yielded statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma
Liso-Cel Confirms Superiority Over SOC in Second-Line LBCL
Second-line lisocabtagene maraleucel reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation.
Armin Ghobadi, MD, on Helping Expand CAR T Cells With NT-I7
The associate professor of medicine at Siteman Cancer Center and WUSTL discussed updated data from a study of NT-I7 and tisa-cel presented at ASH 2022.
Ide-cel Shows Efficacy in Early Relapsed Multiple Myeloma
Patients had an ORR of 83.8% with a median DOR of 15.7 months in data presented at the ASH 2022 meeting.
Steven Pipe, MD, on Continuing Durability of Hemgenix in Hemophilia B
The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed new follow-up data from the HOPE-B study presented at ASH 2022.
Sham Mailankody, MBBS, on Updates on ALLO-715 CAR T in R/R Multiple Myeloma
The associate attending physician at Memorial Sloan Kettering Cancer Center discussed updated data presented at the ASH 2022 meeting.
GPRC5D-Targeted CAR T-Cell Therapy Shows Promising Efficacy After BCMA Therapy in R/R MM
New data from a phase 1/2 trial of BMS-986393 were presented at the 64th Annual ASH Meeting.
David Sallman, MD, on Advantages of Allogeneic CAR T-Cell Therapy in AML
The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.
Akshay Sharma, MBBS, on Inducing Fetal Hemoglobin in Sickle Cell With CRISPR/Cas9-Edited Stem Cells
The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed new data from a phase 1/2 trial presented at ASH 2022.
SPK-8011 Yields Durable FVIII Expression in Hemophilia A
Annualized bleed rate and FVIII infusion rates significantly decreased after infusion with the gene therapy.
Allogeneic CD123 CAR-T Shows Some Clinical Activity in R/R Acute Myeloid Leukemia
Four of 17 patients who received UCART123v1.2 showed clinical benefit.
Gerhard Ehninger, MD, on Beneficial Safety in AML With Rapidly Switchable CAR Therapy
The professor at University Hospital Dresden discussed data presented at the 2022 ASH meeting.
Axi-cel Shows Efficacy in Patients With R/R Aggressive B-Cell Lymphomas Ineligible for HDCT and ASCT
The complete metabolic response rate was 70% 3 months after infusion.
